ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 237

The Risk of Serious and Opportunistic Infections in Rheumatologic Patients on Interleukin Inhibitors: A Systematic Review and Meta-Analysis

Adam Berlinberg1, Jawad Bilal2, Abdullah Alhifany3, Warda Faridi4 and C. Kent Kwoh5, 1Department of Internal Medicine, University of Arizona, Tucson, AZ, 2Internal Medicine, University of Arizona, Tucson, AZ, 3Department of Pharmacy, University of Arizona, Tucson, AZ, 4Department of Hematology/Oncology, University of Arizona, Tucson, AZ, 5Medicine, Division of Rheumatology, University of Arizona School of Medicine, University of Arizona Arthritis Center, Tucson, AZ

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Infection, interleukins (IL) and meta-analysis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 21, 2018

Title: Epidemiology and Public Health Poster I: Rheumatoid Arthritis

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Interleukin (IL) inhibitors are increasingly being used for rheumatologic diseases. There are many controlled clinical trials assessing the efficacy of IL inhibitors, but there are few meta-analyses which have examined the pooled risk of infection with these drugs. Our objective was to assess the risk of serious infection and opportunistic infections in patients with rheumatologic diseases treated with IL inhibitor therapy (anakinra, brodalumab, canakinumab, secukinumab, tocilizumab, olokizumab, ixekizumab, ustekinumab, clazakizumab, and rilanocept).

Methods: Medline via Pubmed, Embase, conference proceedings from ASCO, AACR and ACR and reference lists from published systematic reviews related to rheumatologic diseases and interleukin inhibitors for were searched for RCTs using PICOS strategy. We extracted the incident data for serious infections and opportunistic infections. We conducted a fixed-effect meta-analysis via calculating a pooled odds ratio (Mantel-Haenszel methods with a continuity correction designed for sparse data) using STATA software version 14 (Stata Corp., College Station, Texas, USA). Heterogeneity was assessed using Q-statistic and quantified using I2 statistic.

Results: The initial search of PubMed and Embase yielded 881 citations. We included 38 eligible RCTs that included 16,841 patients. We extracted data on serious infections (death or hospitalization), candidiasis, herpes zoster, and Pneumocystis carinii Pneumonia (PCP) as the main outcomes of interest. Serious infections were significantly more common with patients who received IL inhibitors compared to standard of care (OR 1.97, 95% CI 1.48-2.62) and the heterogeneity was minimal (I2 = 0%, P = 0.99). Moreover, we found that candidiasis also was significantly more common with patients who received IL inhibitors than standard of care (OR 5.41, 95% CI 2.04-14.33; I2 = 0%, P = 0.99). However, we found no significant difference between patients who received IL inhibitors or standard of care in terms of the risk of herpes zoster or PCP (OR 1.23, 95% CI 0.39-3.84; I2 = 0%, p = 0.97 and OR 0.99, 95% CI 0.10-9.65; I2 = 0%, p = 0.70, respectively). There was no increased incidence of secondary assessed opportunistic infections such as TB, non-TB mycobacterium, coccidiodomycosis, histoplasmosis, asperillosis, cryptococcus, etc.

Conclusion: We found an increased risk of serious infections, and a significantly increased risk of candidiasis with the use of IL inhibitors, but there was no appreciable increase in the risk of herpes zoster or PCP. Other opportunistic infections were also found to have no appreciable increased risk. Patients and providers need to remain vigilant in recognizing the risk of serious and opportunistic infections with the use of IL inhibitors, and proper care must be taken to quickly identify and treat any infections as a result of IL inhibitor therapy.


Disclosure: A. Berlinberg, None; J. Bilal, None; A. Alhifany, None; W. Faridi, None; C. K. Kwoh, None.

To cite this abstract in AMA style:

Berlinberg A, Bilal J, Alhifany A, Faridi W, Kwoh CK. The Risk of Serious and Opportunistic Infections in Rheumatologic Patients on Interleukin Inhibitors: A Systematic Review and Meta-Analysis [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/the-risk-of-serious-and-opportunistic-infections-in-rheumatologic-patients-on-interleukin-inhibitors-a-systematic-review-and-meta-analysis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-risk-of-serious-and-opportunistic-infections-in-rheumatologic-patients-on-interleukin-inhibitors-a-systematic-review-and-meta-analysis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology